5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.
Identifieur interne : 000234 ( PubMed/Corpus ); précédent : 000233; suivant : 0002355-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.
Auteurs : Mee-Young Ahn ; Tae-Hyung Kim ; Seong-Min Kwon ; Hyo-Eun Yoon ; Hyung-Sik Kim ; Jae-Il Kim ; Yong-Chul Kim ; Keon-Wook Kang ; Sang-Gun Ahn ; Jung-Hoon YoonSource :
- European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [ 1879-0720 ] ; 2015.
English descriptors
- KwdEn :
- Animals, Antineoplastic Agents (therapeutic use), Apoptosis, Carcinoma, Non-Small-Cell Lung (drug therapy), Cell Cycle (drug effects), Cell Line, Tumor, Humans, Indoles (pharmacology), Indoles (therapeutic use), Lung Neoplasms (drug therapy), MAP Kinase Signaling System (drug effects), Male, Mice, Mice, Nude, Neoplasm Transplantation, Oncogene Protein v-akt (antagonists & inhibitors), Oximes (pharmacology), Oximes (therapeutic use), Receptors, Somatomedin (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Oncogene Protein v-akt, Receptors, Somatomedin.
- chemical , pharmacology : Indoles, Oximes.
- chemical , therapeutic use : Antineoplastic Agents, Indoles, Oximes.
- drug effects : Cell Cycle, MAP Kinase Signaling System.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- Animals, Apoptosis, Cell Line, Tumor, Humans, Male, Mice, Mice, Nude, Neoplasm Transplantation.
Abstract
This study examined the anti-tumor effects of AGM130, a novel indirubin-3'-oxime derivative in A549 human non-small cell lung cancer cells. AGM130 significantly inhibited the proliferation and arrested the cell cycle of G2/M phase. Induction of apoptosis was detected in AGM130-treated A549 cells. The protein levels of Cytochrome c release, Bax, cleaved caspases and PARP were increased in AGM130 treated cells, whereas Bcl-2 levels were decreased. AGM130 inhibited Insulin-like growth factor 1 receptor (IGF1R), AKT/mTOR signaling and inactivated mitogen-activated protein kinases (MAPK). AGM130 also induced slight autophagy as pro-survival function and autophagy inhibition by chloroquine (CQ) induced necrosis. In vivo tumor xenograft model, AGM130 dose-dependently suppressed transplanted A549 cell tumor growth and induced the expression of proliferative cell nuclear antigen (PCNA). AGM130 also increased TUNEL positive apoptotic cell populations and the induction of glandular differentiation with mucin pool compared with vehicle-treated control in tumor tissue. These results suggest that AGM130 is an effective novel indirubin-3'-oxime derivative of anti-cancer drug and may be an attractive candidate for non-small cell lung cancer therapy.
DOI: 10.1016/j.ejps.2015.08.015
PubMed: 26342773
Links to Exploration step
pubmed:26342773Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.</title><author><name sortKey="Ahn, Mee Young" sort="Ahn, Mee Young" uniqKey="Ahn M" first="Mee-Young" last="Ahn">Mee-Young Ahn</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Tae Hyung" sort="Kim, Tae Hyung" uniqKey="Kim T" first="Tae-Hyung" last="Kim">Tae-Hyung Kim</name><affiliation><nlm:affiliation>Division of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kwon, Seong Min" sort="Kwon, Seong Min" uniqKey="Kwon S" first="Seong-Min" last="Kwon">Seong-Min Kwon</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Hyo Eun" sort="Yoon, Hyo Eun" uniqKey="Yoon H" first="Hyo-Eun" last="Yoon">Hyo-Eun Yoon</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Hyung Sik" sort="Kim, Hyung Sik" uniqKey="Kim H" first="Hyung-Sik" last="Kim">Hyung-Sik Kim</name><affiliation><nlm:affiliation>Division of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Jae Il" sort="Kim, Jae Il" uniqKey="Kim J" first="Jae-Il" last="Kim">Jae-Il Kim</name><affiliation><nlm:affiliation>School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712, Republic of Korea; Division of Drug Discovery, Anygen Co., Ltd., Gwangju 500-712, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Yong Chul" sort="Kim, Yong Chul" uniqKey="Kim Y" first="Yong-Chul" last="Kim">Yong-Chul Kim</name><affiliation><nlm:affiliation>School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712, Republic of Korea; Division of Drug Discovery, Anygen Co., Ltd., Gwangju 500-712, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kang, Keon Wook" sort="Kang, Keon Wook" uniqKey="Kang K" first="Keon-Wook" last="Kang">Keon-Wook Kang</name><affiliation><nlm:affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Ahn, Sang Gun" sort="Ahn, Sang Gun" uniqKey="Ahn S" first="Sang-Gun" last="Ahn">Sang-Gun Ahn</name><affiliation><nlm:affiliation>Department of Pathology, College of Dentistry, Chosun University, Gwangju 501-759, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Jung Hoon" sort="Yoon, Jung Hoon" uniqKey="Yoon J" first="Jung-Hoon" last="Yoon">Jung-Hoon Yoon</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea. Electronic address: opathyoon@wku.ac.kr.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26342773</idno><idno type="pmid">26342773</idno><idno type="doi">10.1016/j.ejps.2015.08.015</idno><idno type="wicri:Area/PubMed/Corpus">000234</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000234</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.</title><author><name sortKey="Ahn, Mee Young" sort="Ahn, Mee Young" uniqKey="Ahn M" first="Mee-Young" last="Ahn">Mee-Young Ahn</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Tae Hyung" sort="Kim, Tae Hyung" uniqKey="Kim T" first="Tae-Hyung" last="Kim">Tae-Hyung Kim</name><affiliation><nlm:affiliation>Division of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kwon, Seong Min" sort="Kwon, Seong Min" uniqKey="Kwon S" first="Seong-Min" last="Kwon">Seong-Min Kwon</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Hyo Eun" sort="Yoon, Hyo Eun" uniqKey="Yoon H" first="Hyo-Eun" last="Yoon">Hyo-Eun Yoon</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Hyung Sik" sort="Kim, Hyung Sik" uniqKey="Kim H" first="Hyung-Sik" last="Kim">Hyung-Sik Kim</name><affiliation><nlm:affiliation>Division of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Jae Il" sort="Kim, Jae Il" uniqKey="Kim J" first="Jae-Il" last="Kim">Jae-Il Kim</name><affiliation><nlm:affiliation>School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712, Republic of Korea; Division of Drug Discovery, Anygen Co., Ltd., Gwangju 500-712, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Yong Chul" sort="Kim, Yong Chul" uniqKey="Kim Y" first="Yong-Chul" last="Kim">Yong-Chul Kim</name><affiliation><nlm:affiliation>School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712, Republic of Korea; Division of Drug Discovery, Anygen Co., Ltd., Gwangju 500-712, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Kang, Keon Wook" sort="Kang, Keon Wook" uniqKey="Kang K" first="Keon-Wook" last="Kang">Keon-Wook Kang</name><affiliation><nlm:affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Ahn, Sang Gun" sort="Ahn, Sang Gun" uniqKey="Ahn S" first="Sang-Gun" last="Ahn">Sang-Gun Ahn</name><affiliation><nlm:affiliation>Department of Pathology, College of Dentistry, Chosun University, Gwangju 501-759, Republic of Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Jung Hoon" sort="Yoon, Jung Hoon" uniqKey="Yoon J" first="Jung-Hoon" last="Yoon">Jung-Hoon Yoon</name><affiliation><nlm:affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea. Electronic address: opathyoon@wku.ac.kr.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</title><idno type="eISSN">1879-0720</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antineoplastic Agents (therapeutic use)</term><term>Apoptosis</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Cell Cycle (drug effects)</term><term>Cell Line, Tumor</term><term>Humans</term><term>Indoles (pharmacology)</term><term>Indoles (therapeutic use)</term><term>Lung Neoplasms (drug therapy)</term><term>MAP Kinase Signaling System (drug effects)</term><term>Male</term><term>Mice</term><term>Mice, Nude</term><term>Neoplasm Transplantation</term><term>Oncogene Protein v-akt (antagonists & inhibitors)</term><term>Oximes (pharmacology)</term><term>Oximes (therapeutic use)</term><term>Receptors, Somatomedin (antagonists & inhibitors)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Oncogene Protein v-akt</term><term>Receptors, Somatomedin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Indoles</term><term>Oximes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Indoles</term><term>Oximes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Cycle</term><term>MAP Kinase Signaling System</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Apoptosis</term><term>Cell Line, Tumor</term><term>Humans</term><term>Male</term><term>Mice</term><term>Mice, Nude</term><term>Neoplasm Transplantation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study examined the anti-tumor effects of AGM130, a novel indirubin-3'-oxime derivative in A549 human non-small cell lung cancer cells. AGM130 significantly inhibited the proliferation and arrested the cell cycle of G2/M phase. Induction of apoptosis was detected in AGM130-treated A549 cells. The protein levels of Cytochrome c release, Bax, cleaved caspases and PARP were increased in AGM130 treated cells, whereas Bcl-2 levels were decreased. AGM130 inhibited Insulin-like growth factor 1 receptor (IGF1R), AKT/mTOR signaling and inactivated mitogen-activated protein kinases (MAPK). AGM130 also induced slight autophagy as pro-survival function and autophagy inhibition by chloroquine (CQ) induced necrosis. In vivo tumor xenograft model, AGM130 dose-dependently suppressed transplanted A549 cell tumor growth and induced the expression of proliferative cell nuclear antigen (PCNA). AGM130 also increased TUNEL positive apoptotic cell populations and the induction of glandular differentiation with mucin pool compared with vehicle-treated control in tumor tissue. These results suggest that AGM130 is an effective novel indirubin-3'-oxime derivative of anti-cancer drug and may be an attractive candidate for non-small cell lung cancer therapy. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26342773</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0720</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><PubDate><Year>2015</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</Title><ISOAbbreviation>Eur J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.</ArticleTitle><Pagination><MedlinePgn>122-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejps.2015.08.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0928-0987(15)30004-X</ELocationID><Abstract><AbstractText>This study examined the anti-tumor effects of AGM130, a novel indirubin-3'-oxime derivative in A549 human non-small cell lung cancer cells. AGM130 significantly inhibited the proliferation and arrested the cell cycle of G2/M phase. Induction of apoptosis was detected in AGM130-treated A549 cells. The protein levels of Cytochrome c release, Bax, cleaved caspases and PARP were increased in AGM130 treated cells, whereas Bcl-2 levels were decreased. AGM130 inhibited Insulin-like growth factor 1 receptor (IGF1R), AKT/mTOR signaling and inactivated mitogen-activated protein kinases (MAPK). AGM130 also induced slight autophagy as pro-survival function and autophagy inhibition by chloroquine (CQ) induced necrosis. In vivo tumor xenograft model, AGM130 dose-dependently suppressed transplanted A549 cell tumor growth and induced the expression of proliferative cell nuclear antigen (PCNA). AGM130 also increased TUNEL positive apoptotic cell populations and the induction of glandular differentiation with mucin pool compared with vehicle-treated control in tumor tissue. These results suggest that AGM130 is an effective novel indirubin-3'-oxime derivative of anti-cancer drug and may be an attractive candidate for non-small cell lung cancer therapy. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Mee-Young</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Hyung</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Division of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Seong-Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyo-Eun</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyung-Sik</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Division of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae-Il</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712, Republic of Korea; Division of Drug Discovery, Anygen Co., Ltd., Gwangju 500-712, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong-Chul</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712, Republic of Korea; Division of Drug Discovery, Anygen Co., Ltd., Gwangju 500-712, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Keon-Wook</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Sang-Gun</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Pathology, College of Dentistry, Chosun University, Gwangju 501-759, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jung-Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea. Electronic address: opathyoon@wku.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharm Sci</MedlineTA><NlmUniqueID>9317982</NlmUniqueID><ISSNLinking>0928-0987</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000609730">5-nitro-5'-hydroxyindirubin-3'-oxime</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000597236">IGF1R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010091">Oximes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017451">Receptors, Somatomedin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C474021">indirubin-3'-monoxime</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051058" MajorTopicYN="N">Oncogene Protein v-akt</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017451" MajorTopicYN="N">Receptors, Somatomedin</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AGM130</Keyword><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Indirubin derivative</Keyword><Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>08</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26342773</ArticleId><ArticleId IdType="pii">S0928-0987(15)30004-X</ArticleId><ArticleId IdType="doi">10.1016/j.ejps.2015.08.015</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000234 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000234 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26342773
|texte= 5-Nitro-5'-hydroxy-indirubin-3'-oxime (AGM130), an indirubin-3'-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26342773" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |